Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
7 evidence topics · 6 sources
Summary: anticipated place of dibutepinephrine sublingual film in treatment
Dibutepinephrine sublingual film is an investigational rescue treatment for Type I allergic reactions including anaphylaxis, positioned in the same use setting as an epinephrine auto-injector rather than as a maintenance or preventive therapy. Because most anaphylaxis occurs outside medical settings, the relevant care settings are the community locations where guidelines already direct patients to carry epinephrine: home, school and childcare, restaurants, travel, and workplaces. The 2023 practice parameter update recommends that people at high risk always carry self-injectable epinephrine, and the World Allergy Organization guidance directs that epinephrine be given at the first sign of anaphylaxis and that patients be taught self-administration; a product that removes the needle and the device addresses carriage and hesitation rather than the underlying indication.
The manufacturer describes the product as similar in size to a postage stamp, weighing less than an ounce, beginning to dissolve on contact, and requiring no water or swallowing, with primary packaging thinner and smaller than an average credit card that can be carried in a pocket and is designed to withstand exposure to rain or sunlight. Aquestive states that it is preparing a focused, allergist-first launch, with medical affairs activity directed at the allergy community and partnerships with allergy-focused patient advocacy organizations, and describes the market opportunity as conversion from older autoinjector device technology. The company has not stated that the film would replace an auto-injector for a given patient; the FDA labeling that would define whether it substitutes for or supplements an auto-injector has not been issued, because the application received a Complete Response Letter dated January 30, 2026 and was resubmitted on September 17, 2026. A 2025 review of anaphylaxis management describes sublingual delivery as an alternative developed to address low auto-injector use rather than as a replacement for guideline-recommended intramuscular epinephrine.